Effect of vasoactive intestinal polypeptide (VIP) on glucose and lipid metabolism of isolated rat adipocytes.
The biologic actions of vasoactive intestinal polypeptide (VIP) on insulin binding, glucose uptake and utilization, and on lipolysis were studied. At concentrations between 10(-10) and 10(-7) mol/l VIP influenced neither glucose uptake nor glucose incorporation into lipids under basal and insulin-stimulated conditions. This effect was independent of the presence of adenosine deaminase in the incubation medium. At 10(-8) mol/l VIP increased insulin binding affinity slightly but not significantly, shifting the ID-50 from 12.4 ng/ml to 10.3 ng/ml, without any change in receptor number. However, VIP showed a marked dose-dependent lipolytic activity with the lowest effective concentration at 10(-9) mol/l. At 10(-6) mol/l glycerol release increased 7.3-fold as compared to basal lipolysis. In conclusion, VIP did not affect adipose tissue metabolism at physiologic concentrations. In the rare Verner-Morrison syndrome, however, the potent lipolytic activity of VIP may contribute to the metabolic disturbances observed.
Abteilung Innere Medizin I, Universitätsklinik Ulm, Federal Republic of Germany.
H
H
Hauner
G
G
Glatting
D
D
Kaminska
E F
EF
Pfeiffer
D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D005947:Glucose / Q000378:metabolism*; D008066:Lipolysis / Q000187:drug effects*; D051381:Rats; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D014660:Vasoactive Intestinal Peptide; D005947:Glucose